logo
Share SHARE
FONT-SIZE Plus   Neg

Celgene Reveals Multiple Analyses Data Of Abraxane In Non-Small Cell Lung Cancer

Celgene International Sarl, a subsidiary of Celgene Corp. (CELG: Quote), Sunday revealed data from multiple presentations evaluating Abraxane in combination with carboplatin in patients with advanced non-small cell lung cancer.

The two reports presented data from retrospective analyses of CA-031, the phase III, multi-center, randomized study where patients received either nab-paclitaxel weekly plus carboplatin every three weeks or paclitaxel every three weeks plus carboplatin as first-line therapy for advanced non-small cell lung cancer.

Based on the data from CA-031, Celgene submitted an sNDA for Abraxane for the first-line treatment of patients with advanced non-small cell lung cancer with the U.S. Food and Drug Administration in December 2011. The current PDUFA (Prescription Drug User Fee Act) date for the submission is October 12, 2012.

Results of the study published on April 30, 2012 in the Journal of Clinical Oncology demonstrated a higher overall response rate, the approved primary end-point of the study based on a Special Protocol Assessment, for patients in the nab-paclitaxel arm compared to those in the paclitaxel arm.

The first sub-analysis evaluated elderly patients in the study and patients under 70. In both groups, overall response rate was higher in patients receiving nab-paclitaxel, though the difference was not significant in elderly patients between the arms of the study.

The second report evaluated patients with squamous-cell histology and non-squamous cell patients. The nab-paclitaxel arm demonstrated a significantly higher overall response rate and a slight improvement in overall survival, compared to the paclitaxel arm.

These results are from an investigational study and Abraxane is not indicated in the treatment of non-small cell lung cancer.

CELG traded on Friday at $65.33, down $2.92 or 4.28%, on a volume of 4.5 million shares on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
We are just a few weeks into 2015 and it has already been a busy year for merger deals and merger talks. Here is a list of some of the M&A stories that have made headlines so far in 2015. Diversified electronics maker TE Connectivity Ltd. is nearing a deal to sell its network solutions business unit to CommScope Holding Co., Inc. (COMM) in a deal valued at about $3 billion, according a Wall Street Journal report on Monday. A deal could be announced as early as this week. There has... The video game industry waltzed through 2014 with a record $24 billion in acquisitions and IPOs, says advisory firm Digi-Capital. The frenzied activity in the industry came as companies vied to get hold of game titles that could tilt the scale in their favor, and the need to shore up investment in infrastructure and marketing.
comments powered by Disqus
RELATED NEWS
Trade CELG now with 
Follow RTT